MSLE — Satellos Bioscience Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421642 ·
Ontario, Canada
Last close
$8.70
Market Cap
$184.58M
52W High
$13.40
52W Low
$5.30
ADV30
27,527
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,165,000 | -11,718,000 | 65,769,000 | 7,393,000 | 5,861,000 |
| Mar 2026 | 0 | — | -10,043,000 | -9,768,000 | 75,226,000 | 18,697,000 | 4,563,000 |
| Dec 2025 | 0 | — | -7,647,000 | -7,303,000 | 31,889,000 | 9,804,000 | 4,105,000 |
| Sep 2025 | 0 | — | -5,966,000 | -5,821,000 | 37,503,000 | 19,304,000 | 3,503,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,815,000
Investing CF
$-42,754,000
Financing CF
$54,140,000
CapEx
$-7,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.69
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-91,738,000
Inventory
—
Receivables
$726,000
ST Investments
$51,214,000
EBIT TTM
$-30,023,000
Pretax Income TTM
$-28,358,000
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,459,000 | -24,873,000 | 31,889,000 | 4,105,000 | 27,784,000 | -23,596,000 |
| Dec 2024 | 0 | -20,398,000 | -20,634,000 | 50,747,000 | 3,583,000 | 47,164,000 | -18,252,000 |
| Dec 2023 | 0 | -11,656,113 | -11,977,235 | 33,490,000 | 2,734,000 | 30,756,000 | -8,732,851 |
| Dec 2022 | 0 | -6,209,844 | -8,342,175 | 4,567,492 | 2,085,175 | 2,482,317 | -4,260,978 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.73
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | $184.15M | $4.88 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $186.29M | $3.68 | — |
| ORGO | Organogenesis Holdings Inc. | $181.43M | $1.41 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $181.14M | $1.31 | — |
| PEPG | PepGen Inc. | $179.15M | $2.59 | — |
News headlines (Yahoo Finance, 1h cache)
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application
2026-09-24 16:32 · Yahoo
Satellos Receives FDA Clearance to Study Forazapadin in FSHD
2026-09-24 13:59 · Yahoo
Satellos stock jumps after FDA clears FSHD trial for forazapadin
2026-09-24 13:54 · Yahoo
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to S
2026-09-24 11:00 · Yahoo
Satellos to Present at the 31st Annual Congress of the World Muscle Society
2026-09-15 11:00 · Yahoo
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
2026-09-09 11:00 · Yahoo
Satellos to Participate in Upcoming Investor Conferences
2026-09-01 11:00 · Yahoo
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
2026-08-13 21:02 · Yahoo
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
2026-07-10 19:02 · Yahoo
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
2026-07-08 13:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.